Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Arch Virol. 2012 Feb;157(2):259-69. doi: 10.1007/s00705-011-1164-z. Epub 2011 Nov 11.

Inhibition of fatty acid synthase by amentoflavone reduces coxsackievirus B3 replication.

Author information

  • 1Department of Virology and Antiviral Therapy, University Hospital Jena, Friedrich Schiller University, Hans-Knöll-Str. 2, 07745 Jena, Germany.

Abstract

Coxsackievirus B3 (CVB3) is a human pathogen that causes acute and chronic infections, but an antiviral drug to treat these diseases has not yet been developed for clinical use. Several intracellular pathways are altered to assist viral transcription, RNA replication, and progeny release. Among these, fatty acid synthase (FAS) expression is increased. In order to test the potential of FAS inhibition as an anti-CVB3 strategy, several experiments were performed, including studies on the correlation of CVB3 replication and FAS expression in human Raji cells and an analysis of the time and dose dependence of the antiviral effect of FAS inhibition due to treatment with amentoflavone. The results demonstrate that CVB3 infection induces an up-regulation of FAS expression already at 1 h postinfection (p.i.). Incubation with increasing concentrations of amentoflavone inhibited CVB3 replication significantly up to 8 h p.i. In addition, suppression of p38 MAP kinase activity by treatment with SB239063 decreased FAS expression as well as viral replication. These data provide evidence that FAS inhibition via amentoflavone administration might present a target for anti-CVB3 therapy.

PMID:
22075919
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Springer
    Loading ...
    Write to the Help Desk